← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Complement inhibitors
danicopan
L04AJ09
Adult Dosing
- 150 mg orally three times daily administered with food
- Must be used as add-on therapy to eculizumab or ravulizumab
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Add-on treatment for residual anemia in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have extravascular hemolysis
Mechanism of Action
- Selective inhibitor of complement factor D, preventing cleavage of factor B and assembly of the alternative pathway C3 convertase, thereby mitigating alternative pathway-mediated hemolysis and C3-mediated opsonization
Contraindications
- Patients with unresolved Neisseria meningitidis infection
- Initiation in patients currently not vaccinated against encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae)
Adverse Reactions
- Headache
- Nausea
- Diarrhea
- Arthralgia
- Elevated transaminases
- Serious risk of encapsulated bacterial infections
Drug Interactions
- Strong CYP3A4 inhibitors may increase danicopan exposure
- Strong CYP3A4 inducers may decrease danicopan efficacy
- Substrates of hepatic transporters may be affected
Curated Content: Needs Vetting Before Put to Clinical Use